All News
RheumNow Week in Review – 2 September 2016
Dr. Jack Cush reviews highlights from this week in RheumNow:
Read ArticleRheumNow Week in Review – 22 July 2016
From tofacitinib developmental trials in RA and psoriasis and adherence to T2T in early RA to a rheumatology pearl about dapsone and much more, here are the highlights of what you may have missed on RheumNow.com this week.
Read ArticleIncreaed GI Perforations with Tocilizumab Seen in German Registry Analysis
The issue of lower intestinal tract perforation (LIP) is no novelty to rheumatologists since the RA treatment paradigm shifted from use of NSAIDs (the most common cause of upper GI tract perforations) to steroids and non-steroidal DMARDs.
Read ArticleRheumNow Week in Review – 15 July 2016
Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.
Read Article
EULAR Recommendations for the Management of ANCA-Associated Vasculitis
A EULAR task force has updated its 2009 recommendations for the management of anti-neutrophil cytoplasmic antibody associated vasculitis.
Read Article
GiACTA Study Shows Benefit of Adding Tocilizumab to Steroid Taper in Giant Cell Arteritis
The GiACTA study has published its top line results demonstrating the efficacy of adding tocilizumab (TCZ) to steroid-tapered therapy in patients with giant cell arteritis (GCA).
Read ArticleComorbidities Seen with ANCA-Associated Vasculitis
The damaging potential of many inflammatory disorders is magnified by well-known associated comorbid conditions. This is particularly true in lupus, rheumatoid arthritis and psoriatic disease.
Read ArticleTocilizumab Effective in PMR
Polymyalgia rheumatica (PMR) should be easy and responsive, but it can be a challenge and requires long-term steroid therapy. Problems often begin when steroid–induced side effects take their toll on a patient, especially in elderly adults.
Read ArticleVasculitis Associated with Biologic Use
The widespread use of existing biologics has sometimes been associated with the paradoxical development of biologic-induced autoimmune phenomena, including vasculitis. A recent review of more than 200 vasculitis cases associated with biologic use has profiled the range of these unsual and rare events.
Read Article
Tocilizumab Induces and Maintains Remission in Giant Cell Arteritis
Lancet has reported the results of a randomized, double-blind, placebo-controlled trial of tocilizumab in patients with new-onset giant cell arteritis (GCA).
Read ArticleRelapse Common in ANCA-Associated Vasculitis
Overall survival and survival free of end-stage renal disease (ESRD) have both improved significantly over time in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but the risk of relapse has not.
Read ArticleGCA: Uptick in Severe Infections in First Year
Patients with giant cell arteritis (GCA) had a higher rate of severe infections compared with the general population, a French study found.
Read ArticleShould You Avoid Pneumococcal Vaccine in CAPS and Behcet's Patients
Althought EULAR currently recommends the pneumococcal vaccine be given to patients with inflammatory rheumatic diseases and the Centers for Disease Control and Prevention (CDC) recommends the vaccine in patients treated with immunosuppressive drugs, a recent brief report suggests it be
Read ArticleANA Negative Lupus Nephritis - Does it Exist?
A recent report from the Mayo Clinic describes a 49 year-old patient with lupus nephritis who presented with new-onset hypertension, edema, arthritis, serositis and leukocytoclastic vasculitis, and who later developed glomerulonephritis and nephrotic syndrome.
Read ArticleGame-Changers 2015: Refining Treatment in Arthritis
Widening experience with JAK inhibition for rheumatoid arthritis (RA) and tapering medications among RA patients in remission, along with the success of secukinumab for psoriatic arthritis (PsA), were the most important advances in rheumatology in 2015, according to specialists responding toMedPa
Read ArticleSkin Cancer Risk in ANCA+ Vasculitis
Previously, granulomatous polyangitis (GPA or Wegener's) was known to have an increase risk of cancer, especially bladder cancer, presumeably due to cyclophosphamide (CTX) exposure.
Read ArticleDSB: ACR 2015 Safety Reports
The following is a compilation of abstracts presented at the 2015 Annual ACR meeting in San Francisco. These were chosen on the basis of impact, quality and safety message.
Read ArticleTocilizumab & Abatacept Effective in Giant Cell Arteritis
Giant cell arteritis (GCA) is a medium and large vasculitis, wherein only glucocorticoids (GC) treatment has been the mainstay of therapy. As many will require prolonged treatment, the hazards of GC are well known, lead to substantial toxicity and morbidity.
Read ArticleCryoglobulinemic Vasculitis Reviewed
Cacoub et al review the common entity cryoglobulinemic vasculitis (CryoVas) in the current issue of the American Journal of Medicine.
This small-vessel vasculitis involves the skin, joints, and potentially other organs, including the peripheral nervous system or the kidneys.
Read Article